Last reviewed · How we verify
Dicurin Procaine (MERETHOXYLLINE PROCAINE)
Dicurin Procaine (generic name: MERETHOXYLLINE PROCAINE) is a Small molecule drug developed by Eli Lilly. It is currently FDA-approved (first approved 1982).
Dicurin Procaine is a small molecule that blocks the sodium channel alpha subunit, classified as a blocker. It is a synthetic compound with the synonyms MERETHOXYLINE PROCAINE and PROCAINE MERETHOXYLLINE.
At a glance
| Generic name | MERETHOXYLLINE PROCAINE |
|---|---|
| Sponsor | Eli Lilly |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dicurin Procaine CI brief — competitive landscape report
- Dicurin Procaine updates RSS · CI watch RSS
- Eli Lilly portfolio CI
Frequently asked questions about Dicurin Procaine
What is Dicurin Procaine?
Who makes Dicurin Procaine?
What is the generic name of Dicurin Procaine?
When was Dicurin Procaine approved?
What development phase is Dicurin Procaine in?
Related
- Manufacturer: Eli Lilly — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing